Exploring the impact of Crohn's disease on the intragastric environment of fasted adults.

bile salts intragastric volume osmolality pH pepsin activity surface tension

Journal

ADMET & DMPK
ISSN: 1848-7718
Titre abrégé: ADMET DMPK
Pays: Croatia
ID NLM: 101660124

Informations de publication

Date de publication:
2020
Historique:
received: 02 05 2020
revised: 27 05 2020
entrez: 18 3 2022
pubmed: 15 6 2020
medline: 15 6 2020
Statut: epublish

Résumé

We explored the potential impact of Crohn's disease on the intragastric environment of fasted adults with a view to potential effects on intragastric performance of orally administered drugs in the fasted state. Data were collected from 15 healthy individuals and 15 patients with Crohn's disease. All subjects remained fasted for at least 12h prior to gastroscopy. Intragastric resting volume and pH were measured upon aspiration. Osmolality, surface tension, pepsin activity, and content of six bile acids were measured within 4 months upon sample collection. Unlike intragastric volumes, intragastric osmolality was significantly increased by Crohn's disease. However, mean osmolality value in patients was only slightly higher than in healthy individuals (293 vs. 257 mOsmol/kg, respectively), therefore, unlikely to affect intragastric drug product performance. Primarily due to the high variability of data in healthy individuals, the potential effects on intragastric pH and surface activity could not be evaluated on a statistical basis. However, based on average (mean and median) values, even if they are statistically significant, it seems unlikely to be of clinical significance. Inter-subject variability of pepsin activity, and total bile acids content was high in both the healthy and the patients' groups. Statistical investigation of the potential impact of Crohn's disease on these parameters requires prior designation of the minimum differences to be detected; such differences will determine the minimum sample size required of relevant investigations.

Identifiants

pubmed: 35300366
doi: 10.5599/admet.846
pmc: PMC8915581
doi:

Types de publication

Journal Article

Langues

eng

Pagination

122-128

Informations de copyright

Copyright © 2020 by the authors.

Déclaration de conflit d'intérêts

Conflict of interest: The authors declare that they have no conflicts of interest to disclose.

Références

World J Gastrointest Pharmacol Ther. 2019 Mar 7;10(2):35-49
pubmed: 30891327
J Lipid Res. 2008 Dec;49(12):2690-5
pubmed: 18693215
Eur J Pharm Sci. 2020 Apr 30;147:105280
pubmed: 32109493
Aliment Pharmacol Ther. 2005 Nov 15;22(10):971-9
pubmed: 16268972
J Gen Physiol. 1938 Sep 20;22(1):79-89
pubmed: 19873094
Inflamm Bowel Dis. 2004 Sep;10(5):618-25
pubmed: 15472524
Eur J Pharm Sci. 2019 Jun 15;134:153-175
pubmed: 30991092
Eur J Pharm Sci. 2019 Jun 15;134:31-59
pubmed: 30974173
Dig Dis Sci. 1999 Jul;44(7):1434-9
pubmed: 10489931
Aliment Pharmacol Ther. 1998 Jul;12(7):673-8
pubmed: 9701532
Pharm Res. 2006 Jan;23(1):165-76
pubmed: 16308672
Eur J Pharm Biopharm. 2019 Mar;136:70-83
pubmed: 30579851
Gut. 2001 Apr;48(4):571-7
pubmed: 11247905

Auteurs

Maria Vertzoni (M)

Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece.

Christina Koulouri (C)

Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece.

Androniki Poulou (A)

Department of Gastroenterology, Red Cross Hospital of Athens, Athens, Greece.

Konstantinos Goumas (K)

Department of Gastroenterology, Red Cross Hospital of Athens, Athens, Greece.

Christos Reppas (C)

Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece.

Classifications MeSH